Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer, announced today that Jean de Gunzburg, Scientist and Investor, Founder and Chairman of Zagdanut Ltd, Director of Cardiawave SA, previously CSO and Director of Da Volterra, and Founder and Chairman of Metsya Ltd, has been appointed as a new member of the company’s Board of Directors, effective June 14, 2023. Existing Board Directors Silvio Inderbitzin, Juha Yrjänheikki and Laurent Décory were elected to continue along with Roger Meier as the Chairman of the Board.
Jean brings to the company vast experience as an investor and Board Director in multiple biotechnology companies in the fields of cancer, infectious diseases, molecular diagnostics, cardiology, and vaccine development. Jean is the Founder and Chairman of Zagdanut Ltd, a consulting company in life sciences, and most recently Jean served as a CSO, Director and one of the main investors of Da Volterra, a privately held biotechnology company headquartered in Paris. Prior to that, he was the Founder and Chairman of the consulting company in life sciences Metsya Ltd. From 1978 to 2005, Jean was a cell and molecular biologist who led an academic career with public institutions in the field of cancer research in France. From 1997 to 2005 Jean led the Signal Transduction and Oncogenesis Laboratory at the Institut Curie in Paris. Jean is the author of over 80 publications in international peer-reviewed scientific journals. He holds a Ph. D. in Biology from the University of Paris and did a postdoctoral stay at the Whitehead Institute for Biomedical Research in Cambridge, MA, USA.
“We are thrilled to welcome Jean de Gunzburg to Aurealis Therapeutics’ Board of Directors,” said Juha Yrjänheikki, CEO of Aurealis Therapeutics. “His prestigious and extensive background as an investor and Board Director in different life science companies is impressive. We look forward to his contributions to the company as we move forward with our AUP-16 Phase 2 clinical studies in chronic wounds and accelerate the pre-clinical and clinical development of our lead candidate AUP-55 in oncology.”
“I feel honoured to join the Board of such a greatly promising company. Aurealis Therapeutics has a very seasoned management team that has developed highly innovative technologies harnessing the power of bacteria used as drug producing factories to treat in situ medically unmet devastating diseases such as diabetic foot ulcer, other wounds, and certain types of cancer. Under the helm of its highly experienced Board, I trust that the company is uniquely poised to bring to patients in dire need novel therapies that will considerably enhance their chances of healing and quality of life.”
About Aurealis Therapeutics
Aurealis Therapeutics AG is a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer. The company’s lead clinical assets are the first-in-class four-in-one cell and gene therapies AUP-16 for chronic wounds and AUP-55 for cancers. Aurealis therapies are based on proprietary technology involving genetically engineered Lactococcus Cremoris acting as millions of small immune-activating bioreactors producing multiple human therapeutic proteins (cytokines, growth factors, antibody fragments) to effectively and safely re-educate the distorted host immune microenvironment to a proper state.
For more information:
Laurent Décory, COO
Email: laurent@aurealistherapeutics.com
